<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217320</url>
  </required_header>
  <id_info>
    <org_study_id>Cr in rheumato</org_study_id>
    <nct_id>NCT01217320</nct_id>
  </id_info>
  <brief_title>Creatine Supplementation in Pediatric Rheumatology</brief_title>
  <official_title>Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Creatine supplementation may improve strength, muscle mass, bone mass and muscle function in
      healthy and elderly people. The investigators speculate that creatine supplementation could
      have therapeutic effects in pediatric rheumatic (i.e., juvenile systemic lupus erythematosus
      and juvenile dermatomyositis) patients who usually present muscle weakness, muscle wasting
      and bone mass loss.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle strength</measure>
    <time_frame>after six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>kidney function parameters</measure>
    <time_frame>after six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>after six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle function</measure>
    <time_frame>after six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Juvenile Systemic Lupus Erythematosus</condition>
  <condition>Juvenile Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>creatine supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive 5g/d of creatine monohydrate throughout the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will receive 5g/d of placebo (dextrose) throughout the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>creatine</intervention_name>
    <description>5g/d throughout 12 weeks</description>
    <arm_group_label>creatine supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo (dextrose)</intervention_name>
    <description>5g/d throughout 12 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with lupus systemic erythematosus and juvenile dermatomyositis

          -  physically inactive

          -  stable pharmacological treatment

        Exclusion Criteria:

          -  macroalbuminuria

          -  GFR &lt; 30 mL/min/1.73m2

          -  use of oral anticontraceptive agents

          -  pregnancy

          -  diabetes mellitus

          -  hypothyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Gualano, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eloisa Bonfa, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Gualano, PhD</last_name>
    <phone>551130913096</phone>
    <email>gualano@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05508-30</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Gualano, PhD</last_name>
      <email>gualano@usp.br</email>
    </contact>
    <investigator>
      <last_name>Bruno Gualano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Bruno Gualano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>rheumatology</keyword>
  <keyword>creatine supplementation</keyword>
  <keyword>quality of life</keyword>
  <keyword>strength</keyword>
  <keyword>juvenile systemic lupus erythematosus</keyword>
  <keyword>juvenile dermatomyositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

